NASDAQ:LXRX Lexicon Pharmaceuticals (LXRX) Stock Price, News & Analysis $1.76 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.75 -0.01 (-0.62%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Lexicon Pharmaceuticals Stock (NASDAQ:LXRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get LXRX alerts:Sign Up Key Stats Today's Range$1.70▼$1.7850-Day Range$1.74▼$2.4952-Week Range$1.10▼$2.68Volume3.32 million shsAverage Volume3.37 million shsMarket Capitalization$783.13 millionP/E RatioN/ADividend YieldN/APrice Target$5.70Consensus RatingHold Company Overview Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing medicines for diseases with significant unmet medical needs. The company uses its expertise in human genetics and gene biology to identify novel drug targets and develop small-molecule therapies. Lexicon’s marketed products include XERMELO (telotristat ethyl), an oral treatment for carcinoid syndrome diarrhea in adults whose symptoms are inadequately controlled by short-acting somatostatin analog therapy. The company also developed INPEFA (sotagliflozin), an oral medicine approved in the United States to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart-failure visits in certain adults with heart failure and related conditions. Founded in 1995 and headquartered in The Woodlands, Texas, Lexicon has advanced its products through internal research and collaborations with pharmaceutical partners. Its commercial and licensing relationships have supported the availability of its therapies in the United States and selected international markets. Lonnel Coats serves as the company’s president and chief executive officer.AI Generated. May Contain Errors. Read More Lexicon Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScoreLXRX MarketRank™: Lexicon Pharmaceuticals scored higher than 38% of companies evaluated by MarketBeat, and ranked 709th out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingHold Consensus RatingLexicon Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialLexicon Pharmaceuticals has a consensus price target of $5.70, representing about 223.9% upside from its current price of $1.76.Amount of Analyst CoverageLexicon Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Lexicon Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Lexicon Pharmaceuticals are expected to decrease in the coming year, from ($0.17) to ($0.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lexicon Pharmaceuticals is -11.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lexicon Pharmaceuticals is -11.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLexicon Pharmaceuticals has a P/B Ratio of 5.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Lexicon Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.52% of the float of Lexicon Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverLexicon Pharmaceuticals has a short interest ratio ("days to cover") of 13.4, which indicates bearish sentiment.Change versus previous monthShort interest in Lexicon Pharmaceuticals has recently decreased by 2.36%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLexicon Pharmaceuticals does not currently pay a dividend.Dividend GrowthLexicon Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.42 News SentimentLexicon Pharmaceuticals has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Lexicon Pharmaceuticals this week, compared to 4 articles on an average week.Search Interest5 people have searched for LXRX on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Lexicon Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lexicon Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders14.00% of the stock of Lexicon Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions74.70% of the stock of Lexicon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lexicon Pharmaceuticals' insider trading history. Receive LXRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lexicon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LXRX Stock News HeadlinesComparing Puma Biotechnology (NASDAQ:PBYI) & Lexicon Pharmaceuticals (NASDAQ:LXRX)October 6 at 4:29 AM | americanbankingnews.comLexicon Pharmaceuticals consensus price target increased by 17.91% to $4.64October 2, 2026 | msn.com"The largest market in human history"SpaceX quietly filed paperwork describing what it calls the largest actionable total addressable market in human history, valued at 28.5 trillion dollars. Former Wall Street CEO Dylan says the opportunity has nothing to do with the SpaceX IPO, self-driving cars, or robotics. Instead, it centers on an obscure AI firm Elon has reportedly been paying since 2012.October 8 at 1:00 AM | Behind the Markets (Ad)Lexicon Pharmaceuticals (LXRX) Stock Fair Value Rises After SONATA HCM Trial ProgressOctober 2, 2026 | finance.yahoo.comLexicon Pharmaceuticals: Upgrading On Sotagliflozin HCM Data In Q1 '27 And MoreSeptember 30, 2026 | seekingalpha.comLexicon Pharmaceuticals bondit après une initiation favorable de Cantor FitzgeraldSeptember 29, 2026 | fr.finance.yahoo.comLexicon a new overweight at Cantor on optimism for Inpefa in cardiomyopathySeptember 28, 2026 | seekingalpha.comAktien von Lexicon Pharmaceuticals steigen nach Aufnahme der Beobachtung durch Cantor Fitzgerald mit Overweight-EinstufungSeptember 28, 2026 | de.marketscreener.comDSee More Headlines LXRX Stock Analysis - Frequently Asked Questions How have LXRX shares performed this year? Lexicon Pharmaceuticals' stock was trading at $1.15 on January 1st, 2026. Since then, LXRX stock has increased by 53.0% and is now trading at $1.76. How were Lexicon Pharmaceuticals' earnings last quarter? Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) issued its earnings results on Thursday, August, 6th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by $0.01. The biopharmaceutical company earned $0.69 million during the quarter, compared to analysts' expectations of $3.99 million. Lexicon Pharmaceuticals had a negative net margin of 147.38% and a negative trailing twelve-month return on equity of 37.53%. Read the conference call transcript. How do I buy shares of Lexicon Pharmaceuticals? Shares of LXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lexicon Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lexicon Pharmaceuticals investors own include Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX) and Moderna (MRNA). Company Calendar Last Earnings8/06/2026Today10/08/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (18m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 LXRX's financial health is in the Green zone, according to TradeSmith. LXRX has been in this zone for over 18 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:LXRX Previous SymbolNASDAQ:LEXG CIK1062822 Webwww.lexpharma.com Phone(281) 863-3000Fax281-863-8010Employees81Year Founded1995Price Target and Rating Average Price Target for Lexicon Pharmaceuticals$5.70 High Price Target$8.00 Low Price Target$3.10 Potential Upside/Downside+223.9%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$50.34 million Net Margins-147.38% Pretax Margin-147.38% Return on Equity-37.53% Return on Assets-24.96% Debt Debt-to-Equity Ratio0.29 Current Ratio13.37 Quick Ratio13.29 Sales & Book Value Annual Sales$49.80 million Price / Sales15.73 Cash FlowN/A Price / Cash FlowN/A Book Value$0.30 per share Price / Book5.87Miscellaneous Outstanding Shares444,960,000Free Float382,662,000Market Cap$783.13 million OptionableOptionable Beta1.07 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:LXRX) was last updated on 10/8/2026 by MarketBeat.com Staff. From Our PartnersYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredA simple options setup that cuts through the noiseIan Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, an...TradeWins | SponsoredDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...Porter & Company | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | Sponsored$169 Private Jet Trick ExposedFor $169, a growing circle of travelers are booking private jets without the wait, the hassle, or the high pri...International Living | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexicon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexicon Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LXRX Stock Alerts